Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $103.9 million.

  • Corcept Therapeutics' Shares Outstanding (Weighted Average) rose 53.01% to $103.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.9 million, marking a year-over-year increase of 53.01%. This contributed to the annual value of $103.2 million for FY2024, which is 31.67% down from last year.
  • Latest data reveals that Corcept Therapeutics reported Shares Outstanding (Weighted Average) of $103.9 million as of Q3 2025, which was up 53.01% from $104.1 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Shares Outstanding (Weighted Average) peaked at $116.8 million during Q1 2021, and registered a low of $102.8 million during Q1 2024.
  • For the 5-year period, Corcept Therapeutics' Shares Outstanding (Weighted Average) averaged around $107.2 million, with its median value being $104.9 million (2023).
  • In the last 5 years, Corcept Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 195.77% in 2021 and then tumbled by 925.03% in 2022.
  • Corcept Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $115.7 million in 2021, then fell by 7.67% to $106.8 million in 2022, then dropped by 3.02% to $103.6 million in 2023, then fell by 0.32% to $103.2 million in 2024, then grew by 0.67% to $103.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $103.9 million for Q3 2025, versus $104.1 million for Q2 2025 and $104.1 million for Q1 2025.